In the present study, this heptapeptide KLWVIPQ has been chosen to treat IFN-α-sensitive KT-1/A3 and IFN-α-resistant KT-1/A3R cells to explore the regulatory effects of the IFN-α-sensitive CML cell-binding heptapeptide KLWVIPQ on proliferation, apoptosis, and the related-gene expression of CML cells. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.